论文部分内容阅读
目的评价奥沙利铂(L-OHP)+替加氟(FT-207)+亚叶酸钙(LV)联合沙利度胺治疗晚期胃癌的疗效和毒副反应。方法 43例符合入组条件的晚期胃癌患者随机分为治疗组和对照组。治疗组采用L-OHP+FT-207+LV方案联合沙利度胺治疗,对照组采用L-OHP+FT-207+LV方案化疗。结果治疗组和对照组的有效率分别为47.6%和36.4%,临床获益率分别为76.2%和68.2%,两组比较差异均无统计学意义(P均>0.05)。治疗组的中位生存期优于对照组,但两组生存期的比较差异无统计学意义(P>0.05)。两组患者治疗后生活质量(QOL)评分均有所提高,以治疗组提高最明显(P<0.05)。治疗组恶心呕吐发生率较对照组低,差异有统计学意义(P<0.05),但治疗组嗜睡的发生率较对照组高,差异有统计学意义(P<0.05),其余副作用均相似。结论化疗联合沙利度胺能改善晚期胃癌患者的生活质量,耐受性好,疗效值得进一步研究。
Objective To evaluate the efficacy and toxicity of oxaliplatin (L-OHP) plus Tegafur (FT-207) plus leucovorin (LV) combined with thalidomide in the treatment of advanced gastric cancer. Methods Forty-three advanced gastric cancer patients who met the enrollment criteria were randomly divided into treatment group and control group. The treatment group was treated with L-OHP+FT-207+LV regimen combined with thalidomide, and the control group was treated with L-OHP+FT-207+LV regimen. Results The effective rates of the treatment group and control group were 47.6% and 36.4%, respectively, and the clinical benefit rates were 76.2% and 68.2% respectively. There was no significant difference between the two groups (P>0.05). The median survival time of the treatment group was better than that of the control group, but there was no significant difference in the survival time between the two groups (P>0.05). The quality of life (QOL) scores improved after treatment in both groups, with the most significant increase in the treatment group (P<0.05). The incidence of nausea and vomiting was lower in the treatment group than in the control group (P<0.05). However, the incidence of drowsiness in the treatment group was higher than that in the control group (P<0.05). The other side effects were similar. Conclusions The combination of chemotherapy and thalidomide can improve the quality of life of patients with advanced gastric cancer and have good tolerability. The curative effect is worthy of further study.